Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 10/20 | 0.41 |
| ▸ | HCRTR2 | O43614 | 10/20 | 0.41 |
| ▸ | PRCP | P42785 | 3/20 | 0.41 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.40 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.39 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | HPGDS | O60760 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18462787 | 1.00 | HCRTR1 (0.41) | HCRTR1HCRTR2PRCPCHEK2NR1I2 | |
| SCHEMBL206336 | 1.00 | HCRTR1 (0.41) | HCRTR1HCRTR2PRCPCHEK2NR1I2 | |
| SCHEMBL762064 | 0.97 | PRCP (0.41) | HCRTR1HCRTR2PRCPCHEK2NR1I2 | |
| SCHEMBL206403 | 0.92 | PRCP (0.47) | PRCPNR1I2ABCB11CYP3A4CYP2C9 | |
| SCHEMBL2707855 | 0.92 | PRCP (0.47) | PRCPNR1I2ABCB11CYP3A4CYP2C9 | |
| SCHEMBL2709432 | 0.91 | HCRTR1 (0.44) | HCRTR1HCRTR2PRCPCHEK2NR1I2 | |
| SCHEMBL205792 | 0.91 | HCRTR1 (0.44) | HCRTR1HCRTR2PRCPCHEK2NR1I2 | |
| SCHEMBL17644214 | 0.89 | PRCP (0.46) | HCRTR1HCRTR2PRCPNR1I2ABCB11 | |
| SCHEMBL19339555 | 0.88 | HCRTR1 (0.36) | HCRTR1HCRTR2PRCPCHEK2 | |
| SCHEMBL749228 | 0.88 | PRCP (0.44) | HCRTR1HCRTR2PRCPCHEK2NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088368-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20100310512-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2010-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100310512-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | HCRTR1 4298/4885HCRTR2 4654/4885PRCP 599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.